Previous 10 | Next 10 |
2024-03-07 23:30:29 ET MacroGenics, Inc. (MGNX) Q4 2023 Earnings Conference Call March 07, 2024, 04:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Cal...
2024-03-07 16:12:26 ET More on MacroGenics MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects MacroGenics: Trying To Build A Better Everything MacroGenics Q4 2023 Earnings Preview MacroGenics stock climbs 13% in wake of upg...
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC Preclinical data on two topoisomerase I inhibitor-based ADC product candi...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...
2024-03-05 16:42:18 ET Gainers: Ebang International Holdings ( EBON ) +17% . CrowdStrike Holdings ( CRWD ) +17% . Couchbase ( BASE ) +14% . SOPHiA GENETICS ( SOPH ) +6% . Expensify ( EXFY ) +5% . Losers: ODDITY Tech...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.3% on the day to $20.99. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved p...
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its finan...
2024-02-19 22:23:22 ET Summary MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of metastatic castration-resistant prostate cancer. ...
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.9% on the day to $5.35. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...